News
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
IPG has launched Agentic Systems for Commerce (ASC), to help brands manage the complex commerce ecosystem. To optimize commerce performance, ASC leverages Interpublic’s proprietary agentic system, ...
Tesla expected to post double-digit declines in earnings, sales. Fed chief Powell speech in focus as central bank ...
13h
Zacks Investment Research on MSNHere's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...
Opinion
2dOpinion
Zacks Investment Research on MSNEarly Q2 Results Indicate an Improving Earnings OutlookWe get into the heart of the Q2 earnings season this week, with more than 400 companies on deck to report results, including 109 S&P 500 members. The reporting docket expands beyond the Finance core, ...
Leerink Partnrs has trimmed its Q2 2025 earnings estimate for Merck & Co., Inc., foreseeing a dip to $1.96 per share from ...
In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results